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Diabetic nephropathy is the main cause of end-stage renal dis-
ease. MicroRNAs are powerful regulators of the genome, and
global expression proﬁling revealed miR-21 to be among the
most highly regulated microRNAs in kidneys of mice with
diabetic nephropathy. In kidney biopsies of diabetic patients,
miR-21 correlated with tubulointerstitial injury. In situ PCR
analysis showed a speciﬁc enrichment of miR-21 in glomerular
cells. We identiﬁed cell division cycle 25a (Cdc25a) and cyclin-
dependent kinase 6 (Cdk6) as novel miR-21 targets in me-
sangial cells. miR-21-mediated repression of Cdc25a and
Cdk6 resulted in impaired cell cycle progression and subse-
quent mesangial cell hypertrophy. miR-21 increased podocyte
motility by regulating phosphatase and tensin homolog
(Pten). miR-21 antagonism in vitro and in vivo in streptozoto-
cin-induced diabetic mice decreased mesangial expansion,
interstitial ﬁbrosis, macrophage inﬁltration, podocyte loss,
albuminuria, and ﬁbrotic- and inﬂammatory gene expression.
In conclusion, miR-21 antagonism rescued various functional
and structural parameters in mice with diabetic nephropathy
and, thus, might be a viable option in the treatment of patients
with diabetic kidney disease.
INTRODUCTION
Although diabetic nephropathy (DN) is the most common cause of
end-stage renal disease (ESRD) in the Western world, its molecular
mechanisms are still incompletely understood.1 It involves various
functional and structural renal changes, including renal hyperperfu-
sion and ﬁltration, mesangial matrix expansion and hypertrophy,
basement membrane thickening, accumulation of extracellular ma-
trix (ECM) proteins, and increased capillary permeability to diverse
macromolecules, leading to progressive chronic kidney disease.1
More than 40% of patients with diabetes eventually develop DN.2
Moreover, DN is a strong risk factor for the development of various
macrovascular complications, including atherosclerosis, hyperten-
sion, and stroke.2,3 MicroRNAs (miRNAs) are under intense investi-
gation as powerful regulators of various diseases with potential critical
impact on disease initiation and/or progression, including diabetic
kidney disease.4 miRNAs represent small non-coding RNA tran-
scripts with a length of22 nucleotides, that, through post-transcrip-
tional binding of the 30 UTR of mRNA targets, lead to the repression
of gene and associated protein expression and/or translational inhibi-
tion of protein synthesis.4 Intriguingly, a single miRNA may alter the
expression of a large number of target genes, thus inﬂuencing a spe-
ciﬁc pathology by regulating whole disease-speciﬁc pathways and
signaling cascades rather than a single gene. This unique function un-
derlines the immense importance of these small molecules. miRNAs
can be efﬁciently silenced in vivo by using speciﬁc miRNA antago-
nists.4 Several miRNAs have been described to play a role in DN,
including miR-192 and miR-21.5,6 The role of miR-21 with regard
to DN is still controversial. A previous study reported that genetic
loss of miR-21 is associated with an aggravation of the disease pro-
cess.6 However, a recent study using a mouse model of Alport disease
found pharmacological miR-21 silencing to result in a dramatic
improvement of nephropathy progression by stimulating metabolic
pathways.7 In the present study, we identiﬁed miR-21 by global
miRNA expression proﬁling as one of the major miRNAs upregulated
in the kidneys of diabetic mice as well as in patients with DN.
We describe novel targets of miR-21, including cell division cycle
25A (Cdc25a) and cyclin-dependent kinase 6 (Cdk6). In vivo
treatment with a locked nucleic acid (LNA) targeting miR-21
ameliorated various functional parameters of DN, including tubu-
lointerstitial ﬁbrosis, mesangial matrix expansion, and albuminuria.
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Therefore, pharmacological silencing of miR-21 might be a novel efﬁ-
cient treatment strategy to halt the short- and long-term complica-
tions of DN.
RESULTS
miR-21 in Mice and Humans
In order to identify miRNAs that are critically involved in the devel-
opment of diabetic kidney disease, we performed miRNA proﬁling in
kidneys of healthy and streptozotocin-induced diabetic mice, which
revealed several deregulated miRNAs in diabetic kidneys (Figure 1A).
miR-21 was among the most highly upregulated miRNAs (Figures 1B
and 1C). To investigate the speciﬁc localization of miR-21 upregula-
tion in the kidney, we performed an in situ PCR on kidney sections of
healthy and diabetic mice. In diabetic kidneys, miR-21 was enriched
in all parts of the kidney, with the highest change in glomerular cells
(Figures 1D–1F).
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Figure 1. miR-21 in Diabetic Mice and Diabetic Patients
(A and B) miRNA-array analysis: arrow indicates miR-21 (A), miR-21 array quantification (B), and qPCR validation of miR-21 (C). miR-21 visualization by in situ PCR on kidney
sections of non-diabetic (D) and diabetic (E) mice. (F) Quantification of in situ PCR miR-21 positive (red) staining. (G) Serum miR-21 expression is increased in diabetic patients
compared to healthy controls. (H) Urinary miR-21 expression correlated with proteinuria in diabetic patients. (I) miR-21 expression in human kidney biopsies of diabetic patients
correlated with chronic tubulointerstitial injury (percentage of injury was translated into the following arbitrary scale for further correlation studies: 1%–10% = 1; 11%–20% = 2;
21%–30%=3;31%–40%=4;41%–50%=5;51%–60%=6;61%–70%=7;71%–80%=8;81%–90%=9;91%–100%=10) (I). *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001.
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The plasma miR-21 concentration was increased in diabetic patients
compared to healthy controls (Figure 1G). Furthermore, we show that
urinary miR-21 correlated with proteinuria in patients (Figure 1H).
We recently showed that urinary miR-21 concentration is increased
in type II diabetic patients.8 Interestingly, in patients with diabetic
kidney disease we found a positive correlation of miR-21 expression
with chronic tubulointerstitial injury in kidney biopsies (Figure 1I).
miR-21 Targets Cdc25a and Cdk6, Promoting Cell-Cycle Arrest
in Mesangial Cells
Due to our ﬁndings by in situ PCR regarding the localization of miR-
21 enrichment in DN, we evaluated the molecular mechanisms of
miR-21 in mesangial cells (MCs). Transforming growth factor-b
(TGF-b) is a major pro-ﬁbrotic cytokine and has been shown to be
strongly associated with kidney ﬁbrosis under diabetic conditions.9
TGF-b was signiﬁcantly upregulated after treatment with advanced
glycation end products (AGE-BSAs) in mesangial cells (Figure S1A).
We thus used TGF-b in our in vitro studies. First, we found that the
expression of miR-21 was signiﬁcantly increased in MCs treated with
TGF-b (Figure S1B). MC size was increased by TGF-b treatment
compared to control treatment (Figures 2A, 2B, and 2D). Increased
MC size by TGF-b was normalized by transfection with locked nu-
cleic acids targeting miR-21 (LNA-21) as compared to LNA targeting
a scrambled sequence (LNA-scr), suggesting a crucial role of miR-21
in MC hypertrophy (Figures 2C and 2D).
Long exposure to high glucose or TGF-b treatment arrested MCs in
the G1-phase of the cell cycle and subsequently lead to MC hypertro-
phy.10 We thus assessed whether inhibition of miR-21 prevents cell-
cycle arrest in the G1-phase. TGF-b treatment of MCs conﬁrmed
cell-cycle arrest in G1 (Figures 2E, 2F, and 2H) and reduced prolifer-
ation (Figure S1C). Remarkably, silencing of miR-21 rescued the
TGF-b-induced cell-cycle arrest in G1 (Figures 2G and 2H). In addi-
tion, the number ofMCs treated with TGF-bwas less in S- andM/G2-
phase, respectively (Figures 2E, 2F, 2I, and 2J). Inhibition of miR-21
abrogated the TGF-b-mediated decrease of MCs inM/G2-phase (Fig-
ures 2G and 2J). These results propose miR-21 as a key regulator of
cell cycle progression and prompted us to further investigate targets
of miR-21. Using several bioinformatic algorithms to detect predicted
targets of miR-21 that are involved in cell-cycle regulation, we iden-
tiﬁed Cdc25a and Cdk6 (Figures 2K and 2L). Cdc25a is important for
the activation of cyclin-dependent kinases (Cdks).11 Cdk6 is essential
for cell cycle progression and G1/S transition.12 Consequently, we
show here that silencing of Cdc25a or Cdk6 by small interfering
RNA (siRNA) resulted in G1-phase arrest of the cell cycle (Figures
S2C–S2H). siRNA treatment resulted in a decrease of Cdc25a or
Cdk6 by 50% (Figures S2A and S2B). To conﬁrm the critical roles
of Cdc25a and Cdk6 in cell-cycle regulation and cell proliferation,
we overexpressed these targets in MCs by adenoviral vector transduc-
tion. MCs overexpressing Cdc25a and Cdk6 were detected to a lesser
degree in G0/1 phase and more in S-phase (Figures S3A–S3C).
Furthermore MCs overexpressing Cdc25a and Cdk6 showed signiﬁ-
cantly increased proliferation levels (Figures S3D and S3E). Next,
the regulation of Cdc25a and Cdk6 by miR-21 was assessed on the
protein level. Overexpression of miR-21 by transfection with precur-
sor-miR21 (pre-miR-21) in comparison to a scrambled control (pre-
neg) oligonucleotide showed signiﬁcantly decreased Cdc25a and
Cdk6 (Figures 2M and 2P) protein levels, whereas antagonizing
miR-21 by transfection with LNA-21 in addition to TGF-b treatment
signiﬁcantly increased Cdc25a and Cdk6 (Figures 2N and 2Q) protein
levels, supporting our hypothesis that Cdc25a and Cdk6 are direct tar-
gets of miR-21. To validate these results, we fused either the wild-type
30UTR of Cdc25a and Cdk6 or the 30UTR of both targets, in which the
miR-21 binding sites were mutated, to a Luciferase reporter gene,
respectively. Luciferase activity was signiﬁcantly lower in pre-miR-
21 transfected cells with constructs containing wild-type 30UTR
compared to transfection with pre-neg with wild-type 30UTR and
compared to pre-miR-21 and pre-neg transfected cells, in which the
miR-21 binding sites in the 30UTR were mutated (Figures 2O and
2R). Consequently, we identiﬁed Cdc25a and Cdk6 as novel and
direct targets of miR-21, with a high impact on cell cycle progression
and concomitant MC hypertrophy. Underlining our ﬁnding of cell-
cycle arrest in G1, we found cyclin D1 protein degradation after
TGF-b treatment (Figures S1M and S1N).
Regulation of Inflammation and Fibrosis in MC by miR-21
The expression of pro-ﬁbrotic (TGF-b, Col1a2, ﬁbronectin) as well
as pro-inﬂammatory genes (monocyte chemoattractant protein-1
[MCP-1]) was increased in MCs subjected to AGE-BSAs (Fig-
ure S1A). Likewise, Col1a2, ﬁbronectin, connective tissue growth
factor (CTGF), and TGF-b itself were upregulated after TGF-b
treatment (Figure S1D). To determine the relevance of miR-21 in
ﬁbrotic gene expression, we transfected MCs with precursor-miR-
21 (pre-miR-21) or pre-negative control (pre-neg) oligonucleotides,
locked nucleic acids targeting miR-21 (LNA-21), and additional
TGF-b or locked nucleic acids targeting a scrambled sequence
(LNA-scr) and additional TGF-b (Figures S1E and S1F). Increased
expression of miR-21 resulted in upregulation of CTGF, MCP-1,
Figure 2. Mesangial Cell Hypertrophy Is Induced by miR-21-Mediated Repression of Cdc25a and Cdk6
(A and B) Mesangial cell hypertrophy displayed by F-actin staining (red) after transfection with LNA-scr and either BSA (A) as control (LNA-scr+BSA) or TGF-b (B) treatment
(LNA-scr+TGFb). (C) Inhibition of miR-21 by transfection of LNA-21 and additional TGF-b treatment (LNA-21+TGFb). (D) Quantification of the cell size measurements (n = 5
each). (E–G) DNA histograms showing mesangial cells detected in G0/G1, S, or M/G2 phase of the cell cycle after LNAscr+BSA (E), LNA-scr+TGF-b (F), and LNA-21+TGF-b
(G). (H–J) Quantification of cells detected in G0/G1 phase (H), S phase (I), and M/G2 phase (J) (n = 4). (K and L) Predicted consequential pairing of Cdc25a target region and
miR-21 (K) and of Cdk6 target region and miR-21 (L), respectively (http://www.targetscan.org). (M and P) Western blot (WB) analysis of cytosolic Cdc25a (M) and Cdk6 (P)
after overexpression of miR-21 by transfection with precursor-miR21 (pre-miR-21) in comparison to a scrambled control (pre-neg) oligonucleotide (n = 3). (N and Q) Western
blot (WB) analysis of cytosolic Cdc25a (N) and Cdk6 (Q) after LNA-scr+TGFb and LNA-21+TGFb (n = 3). (O and R) Validation of miR-21 targeting Cdc25a (O) and Cdk6 (R) by
Luciferase activity in relation to b-galactosidase activity after overexpression of miR-21 by transfection with pre-miR-21 in comparison to pre-neg with either wild-type or
mutated target sites of Cdc25a and Cdk6 (n = 3). *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.
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and interleukin-6 (IL-6) (Figure S1G), whereas inhibition of miR-21
was highly protective against TGF-b-mediated upregulation of
TGF-b, MCP-1, and IL-6 (Figure S1H). Investigating possible
signaling pathways, we found that AKT and ERK were highly phos-
phorylated upon TGF-b treatment in MCs (Figures S1I–S1L).
AP-1 as Key Transcriptional Activator of miR-21
Electrophoretic mobility shift assay (EMSA) analysis showed that the
transcription factor AP-1 was highly activated after TGF-b treatment
(Figure 3A). We also detected an increase of primary miR-21 (pri-
miR-21) after TGF-b treatment (Figure 3B), further suggesting tran-
scriptional activation of miR-21 by TGF-b. To test whether inhibition
of AP-1 has an impact onmiR-21 expression, we used the AP-1 inhib-
A B
C D
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Figure 3. AP-1 as Key Transcriptional Activator
of miR-21 in Mesangial Cells
(A) Electrophoretic mobility shift assay showing AP-1
activation as an AP-1/DNA complex (shifted band) after
TGF-b treatment for 2 hr and 24 hr. (B) Every treatment
was assessed in comparison to a competition assay (CA),
respectively. qPCR quantification of primary-miR-21 after
TGF-b treatment (n = 3). (C) AP-1 Luciferase activity in
relation to b-galactosidase activity after an initial increase
of AP-1 activity by phorbol myristate acetate (PMA) and
subsequent AP-1 inhibition by synthetic retinoid 11302
(SR11302) (n = 4). (D–F) qPCR quantification of miR-21
(D), CTGF (E), and Col1a2 (F) after co-treatment with
TGF-b and SR11302 (n = 4). *p < 0.05; **p < 0.01;
***p < 0.001; ****p < 0.0001.
itor synthetic retinoid SR11302. A functional
concentration was determined by fusing AP-1
to a Luciferase reporter gene. The base level of
AP-1 was increased by phorbol myristate ace-
tate, a known activator of AP-1. 10 mM of
SR11302 signiﬁcantly decreased Luciferase ac-
tivity (Figure 3C) and was thus used as a func-
tional concentration for AP-1 inhibition. The
inhibition of AP-1 by SR11302 rescued the
TGF-b-induced upregulation of miR-21, pro-
posing AP-1 as a key transcriptional activator
of miR-21 (Figure 3D). We previously demon-
strated by chromatin immunoprecipitation
(ChIP) analysis using miR-21 promoter primers
encompassing the AP-1 binding site that,
indeed, AP-1 leads to transcription of miR-
21.13 Interestingly, the increased expression
levels of CTGF and Col1a2 in MCs treated
with TGF-b were also normalized by inhibition
of AP-1 (Figures 3E and 3F).
miR-21 Induces Podocyte Motility
Podocyte dysfunction is one of the hallmarks of
diabetic nephropathy.14 In vitro, we found an
increased expression level of miR-21 and Col1a2
in podocytes subjected to TGF-b (Figures 4A and 4B). To test, whether
miR-21 is involved in podocyte dysfunction, we overexpressed and
silenced miR-21 in podocytes. Overexpression of miR-21 increased
podocyte migration, whereas inhibition of miR-21 reduced podocyte
migration (Figures 4C–4H). Silencing of miR-21 enhanced protein
levels of phosphatase and tensin homolog (Pten), identifying Pten as
a bioinformatically predicted (miRTaBase) and experimentally vali-
dated target of miR-21 in podocytes (Figures 4I–4K). To conﬁrm the
functional role of Pten on podocyte motility, we developed a stable
Pten overexpression podocyte cell line. We found that podocytes over-
expressing Pten showed decreased migratory capacities (Figures S3F–
S3H). Podocyte apoptosis was not affected by overexpression of miR-
21 or inhibition of miR-21 under basal conditions (Figures 4L–4Q).
www.moleculartherapy.org
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In Vivo Inhibition of miR-21 Reduces Diabetic Complications
in Mice
Our aforementioned results strongly indicate miR-21 as a powerful
regulator of mesangial cell hypertrophy and podocyte phenotype.
Interestingly, antagonizing miR-21 in vitro prevented these detri-
mental events. We thus translated our in vitro ﬁndings to an in vivo
molecular therapeutic approach in streptozotocin-induced diabetic
mice by treating them with either LNA-21 or LNA-scr (see Fig-
ure S4A for efﬁcacy of LNA-21 treatment; see Table 2 for animal
characteristics).
In line with our in vitro ﬁndings, mesangial expansion was strongly
reduced in mice treated with LNA-21, as assessed by periodic acid-
Schiff (PAS) staining and subsequent mesangial index analysis (Fig-
ures 5A–D). Furthermore, development of interstitial ﬁbrosis, as
detected by Sirius Red staining, was signiﬁcantly increased in the kid-
ney sections of diabetic mice treated with LNA-scr, while LNA-21-
treated mice were protected from collagen accumulation (Figures
5E–H). In addition, increased ﬁbrotic gene expression (Col1a2, Col
III, CTGF, and a-SMA) in DN was successfully rescued by miR-21
silencing (Figures 5N and 5O; Figures S4B and S4C).
The number of inﬁltrating F4/80+ macrophages was signiﬁcantly
attenuated by LNA-21 treatment (Figures 5I–5L). Similarly, mice
treated with LNA-21 were rescued from increased MCP-1 gene
expression (Figure 5P), conﬁrming our histological ﬁnding of reduced
interstitial F4/80+ macrophage inﬁltration (Figures 5I–5L).
Induction of DN resulted in a loss of intraglomerular WT-1+ po-
docytes in LNA-scr-treated diabetic mice, while miR-21 silencing
prevented podocyte loss (Figures 6A–6D). Streptozotozin treatment
resulted in a reduction of podocyte numbers of 20% at week 8 of
hyperglycemia (Figures 6A–6D). This is in line with previous
reports.15
As mentioned above, Ccd25a and Cdk6 were identiﬁed as direct tar-
gets of miR-21. To verify in vivo relevance, we performed Cdc25a and
Cdk6 immunoﬂuorescence stainings on kidney sections. In line with
our in vitro ﬁndings, we found reduced Cdc25a and Cdk6 signals in
the diabetic group, while therapeutic inhibition of miR-21 rescued
both the downregulation of Cdc25a and Cdk6 (Figures 6E–6L).
DN was associated with the development of albuminuria, as expected
(Figure 5M). In line with a prevention of podocyte loss, albuminuria
was signiﬁcantly reduced in mice treated with LNA-21 as compared
to mice treated with LNA-scr oligonucleotides (Figure 5M).
Glycated hemoglobin levels (HbA1c) of mice are shown in Figures
S4D and S4E. LNA-21 treatment resulted in a small non-signiﬁcant
improvement of HbA1c levels.
DISCUSSION
In the present study, we found miR-21 to be increased in streptozo-
tocin-induced diabetic mice through miRNA array analysis. Phar-
macological silencing of miR-21 resulted in amelioration of various
functional and structural parameters in streptozotocin-induced dia-
betic mice, including mesangial matrix expansion, tubulointerstitial
ﬁbrosis, inﬂammatory cell inﬁltration, albuminuria, and podocyte
loss. miR-21 in situ PCR showed a marked enrichment of miR-21
in glomerular cells of mice upon diabetes induction. Moreover, we
found miR-21 played a major role in patients with biopsy-proven dia-
betic kidney disease. miR-21 correlated with chronic tubulointerstitial
injury and the degree of albuminuria. In addition, we show that miR-
21 promotes a G1-phase arrest in MCs by regulating the novel targets
Cdc25a and Cdk6, culminating in MC hypertrophy. The upstream
transcription factor AP-1 was identiﬁed as a pivotal regulator of
miR-21 expression. Furthermore, enhanced levels of miR-21 induced
podocyte motility by regulating Pten. The main results of our study
are summarized in Figure 7.
Several studies have examined the role of miRNAs in the pathogenesis
of DN.4–6 For instance, miR-192 mediates increases in the expression
of collagen I in MCs.5,16 The miR-29 family contributes to hyper-
glycemia-induced podocyte dysfunction17 and progressive renal
inﬂammation and ﬁbrosis in type 2 diabetes.18,19 The Let-7 as well
as the miR-200 families are important regulators of renal ﬁbrosis
related to DN.20–23 miR-21 has been demonstrated to amplify high
glucose-induced mesangial cell pathology in vitro.24 miR-21 in a
mouse model of DN was recently shown to be associated with tubu-
lointerstitial ﬁbrosis by targeting SMAD7 and Pten.25 We performed
a whole genome miRNA expression analysis using pooled total RNA
from kidneys of diabetic and non-diabetic mice. miR-21 was among
the most highly regulated miRNAs in our analysis. Our miRNA
deregulation differs slightly from previous analyses. This might be
due to several reasons. In our experiments, a different strain of
mice (SV129 mice in our study) was used, possibly leading to slight
differences in results (as opposed to the C57BL/6J or DBA2J strains
in previous analyses5,16). Another reason might be the fact that we
investigated type I diabetic animals. Previous analyses focused on
models of type II diabetes.18 The pooling of RNA might also have
impacted the results. However, we give strong evidence regarding
the role of miR-21 in diabetic nephropathy. The analysis of the ther-
apeutic potential of miRNA inhibition in vivo in DN is scarce. Here,
Figure 4. miR-21-Mediated Podocyte Phenotype
(A and B) qPCR quantification of miR-21 (A) and Col1a2 (B) after TGF-b treatment (n = 5). (C–H) Scratch migration for 8 hr in podocytes after pre-miR-21 treatment compared
to pre-neg (C and D) and LNA-21 treatment compared to LNA-scr (F-G); quantification of the cell free area after 8 hr migration (E and H) (n = 6). (I and J) Western blot analysis
of Pten after LNA-21 treatment compared to LNA-scr. (K) Predicted consequential pairing of Pten target region and miR-21 (miRTaBase). (L–Q) Annexin V apoptosis staining
and FACS analysis of cells undergoing early apoptosis (quadrant 3 = Q3) after pre-miR-21 treatment compared to pre-negative controls (L–N) and LNA-21 treatment
compared to LNA-scr (O–Q). RED fluorescence detects the level of cell viability using 7-amino actinomycin D (7-AAD), RED2 fluorescence represents annexin V positivity. *p <
0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.
www.moleculartherapy.org
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we present a comprehensive analysis of the in vivo role of miR-21 in
DN as well as the underlying mechanisms in different cellular com-
partments implicated in DN. In addition, we present evidence of
the therapeutic potential of pharmacological miR-21 silencing in DN.
Contrary to our ﬁndings, genetic loss of miR-21 has recently
been shown to aggravate the progression of DN in mice.6 We found
that diabetic miR-21-deﬁcient TGF-b1-transgenic mice exhibited
increased proteinuria and glomerular extracellular matrix deposition
and podocyte loss. However, our results regarding the pharmacolog-
ical silencing of miR-21 are strongly supported by the Dufﬁeld
group,7 which successfully silenced miR-21 in a genetic mouse model
of Alport nephropathy, resulting in a dramatic improvement of sur-
vival and reduction of albuminuria, glomerulosclerosis, interstitial
ﬁbrosis, tubular injury, as well as inﬂammation. In fact, based on these
results, a clinical phase I trial using miR-21 antagonists in healthy vol-
unteers has already been completed and showed that the drug was
well tolerated and did not show serious adverse events. A clinical
phase II trial is now planned using miR-21 antagonists in patients
with Alport syndrome. The difference between our study and the re-
sults of Lai et al.6 regarding the role of miR-21 in DN might be due to
the fact that genetic loss of miR-21 in the developing embryo might
lead to phenotypic changes beyond context-speciﬁc alterations (dia-
betes) as opposed to the silencing of miR-21 in adult tissue. It is sur-
prising that the silencing of miR-21 in vitro under basal conditions
resulted in a signiﬁcant increase in podocyte apoptosis in the study
by Lai et al., because it is known that unchallenged miR-21 knockout
animals do not have a pathological phenotype.26 If miR-21 silencing
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Figure 5. Molecular Therapeutic Inhibition of miR-21 Reduced Structural Complications in Diabetic Mice
Histological evaluation of therapeutic miR-21 inhibition in diabetic (STZ) mice. (A–D) Mesangial index analysis after periodic acid Schiff (PAS) staining in non-diabetic mice (A),
diabetic mice with LNA-scrambled (B), and LNA-21 treatment (C) as well as quantification of results (D). (E–I) Detection of interstitial collagen by Sirius Red staining in non-
diabetic mice (E), diabetic mice with LNA-scrambled (F), and LNA-21 treatment (G) as well as quantification of results (H). (I–L) Analysis of F4/80 (red) positive macrophage
infiltration in non-diabetic mice (I), diabetic mice with LNA-scrambled (J), and LNA-21 treatment (K) as well as quantification of results (L). (M–P) Urinary albumin:creatinine
ratio (M), qPCR quantification of Col1a2 (N), CTGF (O) andMCP-1 (P) in non-diabetic control mice as well as diabetic mice subjected to LNA-21 and LNA-scr treatment. Non-
diabetic mice, n = 10. Diabetic (STZ) mice treated with LNA-scr, n = 6. Diabetic (STZ) mice treated with LNA-21, n = 5. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.
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in otherwise unchallenged podocytes would result in apoptosis, it
would be expected to also impact the phenotype of miR-21 knockout
animals. In line with this, we did not detect an increase of podocyte
apoptosis under basal conditions. In addition, in the study by Lai
et al.,6 TGF-b transgenic mice were crossed with miR-21 knockout
animals. This highly artiﬁcial model may not reﬂect the in vivo
situation seen in mice with diabetic nephropathy. On the contrary,
the beneﬁcial use of pharmacological miR-21 silencing has been
demonstrated in various renal and extra-renal tissues, thus further
supporting our ﬁndings. For instance, our group was able to demon-
strate that miR-21 silencing in a mouse model of cardiac ﬁbrosis re-
sulted in a dramatic reduction of ﬁbrosis.13,27 Moreover, Dufﬁeld and
co-workers underlined the efﬁcacy of miR-21 silencing regarding
ﬁbrosis development in mice subjected to unilateral ureteral obstruc-
tion.26 In renal ﬁbrosis related to obstructive nephropathy or type II
diabetes, miR-21 silencing has been successfully therapeutically
applied.28,29
Based on our ﬁndings using the in situ PCR technique regarding
the change of expression of miR-21 with diabetes induction,
which mainly showed changes in the glomerular cells, we further
characterized the functional role of miR-21 in vitro using MCs and
podocytes.
MC hypertrophy is one of the earliest deteriorations in DN.1,30,31 In
the interphase of cellular growth, a G1 is separated from S and G2
phases.30 Cells in the G1 phase of the cell cycle can further enter
one of the following paths:32 cells may (1) enter cell division, (2) un-
dergo apoptosis, or (3) arrest at the G1/S transition, which causes an
increase in cell size due to increases in the protein:DNA ratio (hyper-
trophy). Cell cycle progression is positively regulated by cyclins in
complex with cyclin-dependent kinases.32 Here, we introduce a novel
mechanism of cell cycle disturbance by showing that miR-21 directly
targets central positive regulators of G1/S-phase transition. Cdc25a is
crucially involved in the activation of CDKs.11 Additionally, miR-21
represses Cdk6, an essential contributor to cell cycle progression.12
We also demonstrate that silencing of miR-21 targets Cdc25a and
Cdk6, which results in G1-phase arrest, while viral overexpression
promotes cell cycle progression, further underlining their impor-
tance. Taken together, our study indicates that the degradation of
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Figure 6. Molecular Therapeutic Inhibition of miR-21 Reduced Functional Complications in Diabetic Mice
(A–D) Determination of WT-1 (red) positive podocyte loss in non-diabetic mice (A), diabetic mice with LNA-scrambled (B), and LNA-21 treatment (C) as well as quantification
of results (D). (E–H) Cdc25a immunofluorescence staining in non-diabetic mice (E), diabetic mice with LNA-scrambled (F), and LNA-21 treatment (G) as well as quantification
of results (H). (I–L) Cdk6 immunofluorescence staining in non-diabetic mice (I), diabetic mice with LNA-scrambled (J), and LNA-21 treatment (K) as well as quantification of
results (L). Non-diabetic mice, n = 10. Diabetic (STZ) mice treated with LNA-scr, n = 6. Diabetic (STZ) mice treated with LNA-21, n = 5. *p < 0.05; **p < 0.01; ***p < 0.001;
****p < 0.0001.
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two proteins, necessary for G1/S phase transition, ﬁnally results in
MC hypertrophy in vitro and in vivo. This is the ﬁrst report showing
that Cdc25a and Cdk6 are targeted by miR-21 in MCs under diabetic
conditions. Cdc25a has previously been identiﬁed to be targeted by
miR-21 in colon cancer cells.33Moreover, we show that CTGF is regu-
lated by miR-21 and that AKT signaling is activated by TGF-b. Pre-
vious reports show that CTGF reduced G1/S-phase transition34 and
that activation of AKT signaling lead to MC hypertrophy,35 further
supporting our ﬁndings.
Inﬂammation is another important mechanism in MCs. IL-6 is
associated with mesangial expansion in diabetic patients.36,37 We
demonstrate that overexpression of miR-21 enhanced both IL-6
and MCP-1 expression. Thus, we propose that miR-21 is crucially
involved in pro-inﬂammatory processes in MCs. Inﬂammation as
well as pro-ﬁbrotic processes were rescued by miR-21 silencing.
This is in line with an amelioration of inﬂammatory gene expression
as well as macrophage inﬁltration in whole kidneys of mice by miR-
21 silencing in our study. The main ﬁndings in MCs are summa-
rized in Figure S5.
Podocytes are functionally and structurally injured in the diabetic
state.14 Here, we show that miR-21 is crucially involved in podocyte
motility by regulating Pten. We demonstrate that podocytes stably
overexpressing Pten exhibit decreased migratory capacity, further
underlining its importance for podocyte biology. miR-21-medi-
ated podocyte motility suggests that miR-21 might be involved in
enhanced leakiness of the slit diaphragm contributing to albuminuria.
In vivo, therapeutic inhibition of miR-21 prevented podocyte loss and
Figure 7. Summary of the Main Results
High glucose under diabetic conditions leads to an in-
crease in TGF-b. miR-21 targets Cdc25a and Cdk6 in
mesangial cells (turquoise), leading to mesangial cell hy-
pertrophy by inducing a G1-phase arrest. miR-21 targets
Pten, leading to increased podocyte motility and extra-
cellular matrix production (orange). miR-21 leads to
extracellular matrix accumulation (purple). These mecha-
nisms contribute to diabetic kidney disease. miR-21
silencing ameliorates these phenomena.
albuminuria, underlining the beneﬁcial effects of
an anti-miR-21 therapeutic strategy in podo-
cytes. These ﬁndings are in line with Lin
et al.,38 indicating that Pten inhibition stimulates
podocyte cytoskeletal rearrangement, leading to
albuminuria. Moreover, Pten overexpression in
podocytes has been shown to result in normali-
zation of high glucose-induced phenotypic tran-
sitions and prevention of nephrin loss.39
Although several advances in the treatment of
DN have been initiated, including effective
blood pressure and blood glucose control, DN
and its complications still pose a major risk factor for the develop-
ment of end stage renal disease. By antagonizing miR-21 in vivo,
we found several functional and structural parameters in DN to be
successfully ameliorated.
In conclusion, our results described herein reveal that miR-21 is an
important regulator of DN progression. miR-21 is mainly enriched
in glomerular cells in DN, promoting cell-cycle arrest and subse-
quent MC hypertrophy by targeting Cdc25a and Cdk6 and leading
to podocyte dysfunction by regulating Pten. Therapeutic miR-21 in-
hibition resulted in amelioration of various functional endpoints
and is thus a promising future therapeutic in the treatment of pa-
tients with diabetic kidney disease. We administered LNAs targeting
miR-21 at weeks 2 and 5. This is in line with a report showing that
administration of a single dose of a locked nucleic acid targeting
miR-21 results in a strong silencing of miR-21 in the kidney for
at least 21 days.40 Since 21 days is the latest time point assessed
in this study, it can be inferred that miR-21 silencing is sustained
for much longer periods of time. Several clinical trials involving
miRNA-therapeutics have been or will be initiated: anti-miR-21
treatment in patients with Alport nephropathy, anti-miR-122 treat-
ment in patients with hepatitis C virus infection, and anti-miR-221
treatment in patients with hepatocellular carcinoma. The emergence
of these clinical trials underscores the potential therapeutic signiﬁ-
cance of anti-miR-strategies in the future routine treatment of pa-
tients. Our results regarding the successful use of miR-21 silencing
in a murine model of DN suggest that miR-21 antagonism might be
a viable therapeutic option in future clinical trials involving patients
with DN.
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MATERIALS AND METHODS
Patients
Patient characteristics are described in Table 1. The ethical committee
of the University Hospital Jena approved the study. 26 patients and 20
age-matched healthy controls were included. The diagnosis of diabetic
nephropathy (or diabetic kidney disease [DKD]) was histologically
conﬁrmed after kidney biopsy in 11 patients. Biopsies were evaluated
by an experienced renal pathologist, including the quantiﬁcation of
chronic tubular damage of the renal cortex in percent.
Animal Studies
Male SV129 mice (Charles River) were housed under standard condi-
tions. Mice 8- to 10-weeks old and weighing between 20 and 30 g were
used for all experiments. All procedures were carried out according
to guidelines from the American Physiological Society and were
approved by local authorities. All animal experiments were per-
formed at Semmelweis University. The animals received a standard
diet with free access to tap water. The Low-Dose Streptozotocin In-
duction Protocol according to the Animal Models of Diabetic Com-
plications Consortium (AMDCC) was used. Weight-matched mice
were fasted for 4 hr prior to injection. Mice then received 50 mg/kg
body weight streptozotocin (STZ) (Sigma-Aldrich) in 100 mmol/L
sodium citrate (pH 4.5) or sodium citrate buffer (control, n = 10)
intraperitoneally for 5 consecutive days. Glucose levels from tail blood
were measured with the glucometer Elite (Bayer) every day. Animals
with glucose levels > 16 mmol/L on two consecutive measurements
were regarded as hyperglycemic, and glucose measurements were
extended to once weekly. Body weight was assessed at baseline and
weekly during the course of the study. The mice received no insulin
within the complete study period. Ketonuria did not occur (data
not shown). Urine samples were taken every week to determine albu-
minuria levels as described previously.41 After 8 weeks of hyperglyce-
mia, the animals were sacriﬁced according to the following protocol.
After anesthesia with avertin (2.5%), a laparotomy was performed,
and urine was collected by puncturing the bladder with a 23-gauge
needle. The abdominal aorta was canulated with a 23-gauge needle,
and the organs were perfused with lactated Ringer solution. Table 2
shows animal characteristics.
LNA-Modified miRNA Oligonucleotides
The oligonucleotides were provided by Exiqon. Mice (n = 5 in
LNA-21 STZ group, n = 6 in LNA-scr STZ group) were treated
intraperitoneally with either locked nucleic acids targeting miR-21
(LNA-21) or targeting a scrambled mismatch sequence (LNA-scram-
bled) at a dose of 20 mg/kg body weight each at weeks 2 and 5 after
STZ injection.
miRNA Global Transcriptome Analysis
miRNA expression analysis was performed in kidneys of diabetic and
non-diabetic wild-type mice. Pooled total RNA from ﬁve mice with
DN and ﬁve healthy control mice was used for genome-wide miRNA
array analysis. The Affymetrix miRNA Gene- Chip array analysis
was used according to the manufacturer’s instructions (Affymetrix).
The Cluster Gene 3.0 Program was used for analysis. Data was log
transformed and genes and arrays were centered. Genes and arrays
were ﬁnally clustered by Spearman rank correlation and average
linkage.
miRNA and RNA Isolation and miRNA and mRNA RT-PCR
RNA isolation was performed with peqGold Trifast (VWR Peqlab)
according to the manufacturer’s instructions. For detection of
miRNAs in samples, TaqMan miRNA assays (Applied Biosystems)
were applied. RNU-6B was ampliﬁed as a control. RT-PCR analysis
was performed (ICycler, Bio-Rad). Ampliﬁed cDNA was used as a
template for qPCR (ViiA 7 Real-Time PCR System, Life Technolo-
gies). For detection of mRNAs in samples, RT was performed with to-
tal RNA using oligoDT primers (Bio-Rad). Ampliﬁed cDNAwas used
as a template for qPCR. qPCR analysis was performed (CFX96 Touch
Real-Time PCR Detection System, Biorad) with iQTM SYBR Green
Supermix (Biorad). The primers used in our study are depicted in
Table S1.
miRNA-21 In Situ PCR
Sections (4 mm in thickness) from 4% paraformaldehyde (PFA)-
ﬁxed and parafﬁn-embedded kidney tissue were deparafﬁnized and
digested with pepsin (Dako, Agilent Technologies) dilution for
20 min. The sections were treated with DNase I (Roche) overnight.
Afterward, the tissue section was covered with the miRNA PCR
Table 1. Demographic and Clinical and Laboratory Characteristics of
Patients
Total Male Female
Number of patients (n) (%) 26 20 (77) 6 (23)
Age (years) 63.2 ± 2.1 64.7 ± 2.5 58.2 ± 4.2
Serum creatinine (umol/L) 246.7 ± 30.8 256.6 ± 37.4 213.8 ± 50.3
GFR (mL/min/m2) 31.0 ± 3.3 30.6 ± 3.7 32.2 ± 8.2
MAD (mm Hg) 103.8 ± 1.6 103.2 ± 1.9 105.7 ± 3.5
C-reactive protein (mg/L) 13.9 ± 4.1 14.0 ± 5.2 13.9 ± 4.8
Proteinuria (g/L) 3.1 ± 0.4 2.7 ± 0.4 4.8 ± 0.15
Concomitant Drug Treatment
ARB (n) (%) 16 (62) 12 (46) 4 (15)
ACE inhibitors (n) (%) 14 (54) 12 (46) 2 (8)
Beta-blocker (n) (%) 22 (85) 18 (69) 4 (15)
Calcium channel blocker (n) (%) 22 (85) 17 (65) 5 (19)
Loop diuretics (n) (%) 23 (88) 19 (35) 4 (15)
Statins (n) (%) 17 (65) 14 (54) 3 (12)
Aspirin (n) (%) 14 (54) 12 (46) 2 (8)
Insulin (n) (%) 13 (50) 12 (46) 1 (4)
Metformin (n) (%) 3 (12) 3 (12) 0 (0)
Glimepiride (n) (%) 5 (19) 2 (8) 3 (12)
ESA (n) (%) 3 (12) 3 (12) 0 (0)
ARB, angiotensin receptor blocker; ACE inhibitor, angiotensin converting-enzyme in-
hibitor; ESA, erythropoietin stimulating agent; GFR, glomerular ﬁltration rate; MAD,
mean arterial pressure. Data are presented as mean ± SEM.
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solution, consisting of miR-21 primers (RT: 50-GTCGTATCCA
GTGCAGGGTCCGAGGTATTCGCACTGGATACGACTCAACA;
forward: 50- TGCGGTAGCTTATCAGACTGA; reverse: 50-GTGC
AGGGTCCGAGGT), digoxigenin dUTP (Roche), RNase inhibitor
(Roche), and SuperScript One-Step RT-PCR System with Platinum
Taq DNAPolymerase (Life Technologies). The corresponding primer
for cel-miR-39 (RT: 50- GTCGTATCCAGTGCAGGGTCCGAGG
TATTCGCACTGGATACGACCAAGCT; forward: 50-GCCCTCA
CCGGGTGTAAAT; reverse: 50-GTGCAGGGTCCGAGGT) was
used as negative control. cDNA synthesis was performed by incu-
bating slides for 30 min at 60C. Then cDNA was ampliﬁed after
denaturing at 94C for 4 min with 26 cycles at 94C denaturation
(15 s), 56C annealing (30 s), and 72C extension (20 s) followed
by ﬁnal extension at 72C for 5 min. The digoxigenin-labeled miRNA
cDNA was detected with a digoxigenin antibody (Roche).
Histology and Immunostaining
After kidney extraction, a representative part of each kidney was ﬁxed
immediately in PBS-buffered 4% paraformaldehyde and embedded in
parafﬁn. Sections (4 mm in thickness) were used for immunostainings,
periodic acid-Schiff (PAS), and Sirius Red stainings. PAS staining was
used to evaluate mesangial expansion by mesangial index (MI) deter-
mination according to the protocol of the Animal Model of Diabetic
Complications Consortium (AMDCC): area (pixel) of PAS staining /
total area (pixel) of glomerulus. MI was examined in at least 30
glomeruli per animal. Collagen accumulation was assessed by Sirius
Red staining: area (pixel) of Sirius Red staining / total kidney area
(pixel), displayed in percentage of ﬁbrosis. In vitro, mesangial hyper-
trophy was assessed by measuring cell size after phalloidin-TRITC
(Sigma-Aldrich) staining F-actin in the cytoplasm of cells.
Immunostainings
Deparafﬁnized kidney sections were boiled in citrate buffer for anti-
gen retrieval, blocked with 5% donkey serum, and incubated over-
night at 4C with primary antibodies. This was followed by antibody
visualization using Alexa 488/Alexa 594 secondary antibodies
(Molecular Probes/Invitrogen). Immunostainings for inﬂammatory
cell inﬂux was performed using the following primary antibody:
monoclonal rat anti-mouse F4/80 (Serotec). Quantiﬁcation of F4/
80-expressing cells was performed by counting positive cells in ﬁve
randomly chosen non-overlapping ﬁelds. Immunostainings for podo-
cyte number per glomerular tuft were performed in frozen sections
using the following primary antibody: polyclonal rabbit anti-mouse
WT-1 (Santa Cruz Biotechnology). Here, podocyte density was as-
sessed by counting at least 30 glomeruli of each section by nuclear
(Dapi-staining) and podocyte (WT-1 staining) as described previ-
ously.7 Immunostainings of miR-21 targets were performed in
frozen sections using the following primary antibodies: monoclonal
mouse anti-mouse/rat/human Cdc25a (Santa Cruz Biotechnology)
and monoclonal mouse anti-mouse/rat/human Cdk6 (Abcam).
Cell Culture Experiments
For in vitro analyses, a mouse mesangial cell line and aWT5 podocyte
cell line were used. Mesangial cells were cultured in DMEM (Life
Technologies) supplemented with 10% FCS and 1% penicillin or
streptomycin. For proliferation, the WT5 podocyte cell line was
cultured under permissive conditions at 33C with RPMI (Life Tech-
nologies) supplemented with 10% FCS, 1% penicillin or streptomycin,
and 100 U/mL IFN-g. For differentiation prior to experiments, the
WT5 podocyte cell line was cultured under non-permissive condi-
tions at 37C with RPMI (Life Technologies) supplemented with
Table 2. Animal Characteristics: Glycemia, Glucosuria, and Body Weight
Mice Week 0 Week 1 Week 2 Week 3 Week 4 Week 5 Week 6 Week 7 Week 8
Glycemia (mmol/L)
Non-diabetic 6.8 ± 1.2 6.7 ± 1.0 6.7 ± 0.6 6.4 ± 0.7 6.2 ± 0.6 6.4 ± 1.2 5.7 ± 1.2 5.4 ± 0.6 5.9 ± 0.8
Diabetic+ LNA-scr 18.5 ± 1.5 19.5 ± 2.6 22.7 ± 2.0 24.5 ± 2.4 21.8 ± 2.3 22.8 ± 2.6 23.5 ± 2.5 23.3 ± 4.2 22.5 ± 3.1
Diabetic+ LNA-21 17.9 ± 1.2 21.2 ± 2.1 20.8 ± 2.4 20.0 ± 4.4 19.8 ± 3.8 18.4 ± 3.9 20.8 ± 2.6 20.0 ± 1.5 21.1 ± 5.0
p valuea 0.45 0.26 0.19 0.06 0.19 0.05 0.11 0.17 0.57
Glucosuria (mmol/L)
Non-diabetic 0.5 ± 0.3 – – – 0.4 ± 0.2 0.4 ± 0.2 0.4 ± 0.3 0.4 ± 0.1 0.4 ± 0.2
Diabetic+ LNA-scr 0.6 ± 0.4 – – – 74.4 ± 54.0 104.4 ± 41.7 116.4 ± 21.2 126.7 ± 2.9 127.5 ± 1.3
Diabetic+ LNA-21 0.9 ± 0.9 – – – 42.1 ± 49.0 55.7 ± 54.3 117.9 ± 13.8 101.7 ± 32.7 92.2 ± 40.9
p valuea 0.52 – – – 0.33 0.13 0.90 0.09 0.06
Body Weight (g)
Non-diabetic 25.4 ± 1.7 26.4 ± 1.5 27.3 ± 1.6 27.6 ± 1.3 27.8 ± 1.7 28.4 ± 1.5 27.6 ± 1.6 28.1 ± 1.9 28.4 ± 1.9
Diabetic+ LNA-scr 23.5 ± 1.7 23.6 ± 1.7 23.8 ± 1.6 23.3 ± 2.0 23.5 ± 2.0 23.9 ± 1.6 24.1 ± 2.2 24.1 ± 2.2 24.3 ± 2.0
Diabetic + LNA-21 24.5 ± 1.7 24.6 ± 1.5 24.3 ± 1.2 24.6 ± 1.0 24.64 ± 1.3 25.1 ± 1.4 24.8 ± 0.8 25.7 ± 1.5 26.0 ± 1.4
p valuea 0.40 0.43 0.35 0.32 0.40 0.41 0.50 0.25 0.15
Data are presented as mean ± SD.
aLNA-scr versus LNA-21.
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10% FCS, 1% penicillin or streptomycin and without IFN-g. Cells
were grown to 60% to 70% conﬂuence and used for further down-
stream analyses. Cells were treated with TGF-b at a concentration
of 4 ng/mL (mesangial cells) or 10 ng/mL (WT5 podocytes) or with
advanced glycation end products at a concentration of 100 mg/mL
(AGE-BSA, Millipore) for 24 hr. BSA is widely used as a carrier pro-
tein to enhance the stability of recombinant proteins. Thus, we
decided to use BSA without TGF-b as the control treatment to elim-
inate possible effects of BSA itself.
Transfection Assays
Transient liposomal transfections with locked nucleic acids targeting
miR-21 (LNA-21, Exiqon) or locked nucleic acids targeting a
mismatch sequence (LNA-scrambled, Exiqon), precursor-miRNA-
21 (pre-miR-21, Ambion) or pre-negative control (pre-neg, Ambion)
oligonucleotides, as well as small interfering RNA (Santa Cruz
Biotechnology) silencing Cdc25a, Cdk6, or a control siRNA were per-
formed according to the manufacturers’ instructions. Brieﬂy, cells
were split 1 day before transfection to reach 60% to 70% conﬂu-
ence on the day of transfection. Speciﬁc LNA-21/pre-miR-21 and
scrambled controls (LNA-scr/pre-neg) and Lipofectamine 2000 (In-
vitrogen) were mixed separately and incubated for 5 min with
Opti-MEM I media (Invitrogen). Complexes were added together
and incubated for 20 min. Media were changed to antibiotic-free me-
dia before the addition of liposomal LNA/pre-miR complexes (ﬁnal
concentration 100 nmol/L). Cells were incubated for 4 hr before the
media were changed to fresh media. Cells transfected with LNA
were additionally treated with 4ng/mL TGF-b (mesangial cells) to
mimic therapeutic effects under diabetic conditions or 0.1% BSA as
control for the last 24 hr of transfection. Silencing or augmenting
of miRNA targets was monitored after 48 hr of transfection by west-
ern blot analysis.
Protein Analysis
Western blot analysis was performed using 10 to 40 mg of total pro-
tein. Tissue was homogenized and cells were pelleted. Cell lysis was
performed (cell lysis buffer, Cell Signaling Technology) and protein
electrophoresis was initiated. Proteins were transferred to polyviny-
lidene diﬂuoride (PVDF) membranes, blocked with 5% milk
in TBS-Tween, and probed overnight at 4C with the following
primary antibodies: Cdc25a (rabbit anti-mouse/human, Abcam),
Cdk6 (mouse anti-mouse/rat/human, Abcam), phospho-AKT
(ser) (rabbit anti-mouse/rat/human, Cell Signaling Technology),
AKT (rabbit anti-mouse/rat/human, Cell Signaling Technol-
ogy), phospho-ERK (44/42) (rabbit anti-mouse/rat/human, Cell
Signaling Technology), ERK (rabbit anti-mouse/rat/human, Cell
Signaling Technology), CyclinD1 (mouse anti-mouse, Santa Cruz
Biotechnology). Antibody binding was visualized by chemilumines-
cence (Super-Signal West Pico Chemiluminescent, Thermo Fisher
Scientiﬁc). Rabbit anti-mouse glyceraldehyde 3-phosphate dehy-
drogenase (GAPDH; Sigma-Aldrich) was used as an internal
loading control and for normalization of protein quantiﬁcation.
Immunoblots were scanned and quantiﬁed using ImageJ densitom-
etry software.
MicroRNA Target Prediction
The microRNA databases and target prediction tools miRBase,
DIANA-MICROT, MICRORNA.ORG, MIRDB, RNA22-MMU, and
TARGETSCAN-VERT were used to identify potential microRNA
targets.
Luciferase Reporter Assays
A luciferase reporter assay system was applied to validate potential
miRNA targets as described previously.42 A putative 30UTR miRNA
binding sequence was cloned into the SpeI and HindIII cloning
site of pMIR-REPORT vector (Ambion): cell division cycle 25a
(Cdc25a) wild-type: 50-TCAGA.CTGACATAAGCTAAATC...TC
CAT-30; cyclin-dependent kinase 6 (Cdk6) wild-type: 50-TCA
TT.CCCAAATAAGCTGCATG...TCATG-30. A mutation of the
miR-21 binding site was also performed by gene synthesis of Cdc25a
and Cdk6 30UTR encompassing mutated target sequences of miR-21
by Euroﬁns Genomics: mutated cell division cycle 25a (Cdc25a):
50-TCAGA.CTGACATAGTATAAATC...TCCAT-30; mutated cy-
clin-dependent kinase 6 (Cdk6): 50-TCATT.CCCAAATGGTCTG
CATG...TCATG-30. These were also cloned into pMIR-REPORT vec-
tor (Ambion) between SpeI and HindIII sites. The resulting constructs
were co-transfected with the miRNAs of interest and a b-galactosidase
control plasmid (Promega) intoHEK293 reporter cells in 48-well plates
by use of Lipofectamine 2000 (Invitrogen). A total of 0.2 mg of plasmid
DNA and 100 nmol/L miRNA was applied. Cells were incubated for
24 hr before luciferase and b-galactosidase activity was measured
(Promega).
Cell Cycle Analysis
Labeling of cellular DNA with propidium iodide was performed
to determine cells in different stages of the cell cycle using Guava
Cell Cycle Reagent (Guava Technologies) according to the
manufacturer’s instructions. Cell cycle analysis was performed
by ﬂuorescence-activated cell sorter analysis (FACS) on a Guava
easyCyte sorter (Millipore) using the Cytosoft software (Guava
Technologies).
Proliferation Assay
Bromodeoxyuridine (BrdU) Cell Proliferation ELISA Kit (Abcam)
was used to measure the proliferation rate. The assay was performed
according to the manufacturer’s instructions.
EMSA
EMSA “Gel Shift” Kit (Affymetrix) and EMSA Probe Set (Pano-
mics) were used to detect transcriptional activation of AP-1 ac-
cording to the manufacturer’s instructions. In brief, EMSA is based
on the separation of unbound DNA from AP-1/DNA complexes
due to differences in electrophoretic mobility in native polyacryl-
amide gels. The gel is transferred to a nylon membrane and de-
tected using strepatvidin-HRP and a chemiluminescent substrate.
The shifted bands corresponding to the protein/DNA complexes
are visualized relative to the unbound double-stranded DNA
(dsDNA). For more speciﬁc binding, unlabeled speciﬁc dsDNA
probe (competition assay) was added to the protein/DNA reaction
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mixture, which competes with the labeled dsDNA probe (biotin-
labeled probe) for binding to the protein. This causes the labeled
probe to migrate to the bottom of the gel and reduces the intensity
of the shifted band.
Transcriptional Activation Studies
Synthetic retinoid 11302 (SR11302, R&D Systems) was used to
inhibit AP-1 activity. A functional concentration of SR11302 was
determined by co-transfection of an AP-1 plasmid (4AP-1 lucif-
erase reporter plasmid [4AP-1-Luc]) with a b-galactosidase con-
trol plasmid (Promega) into HEK293 reporter cells in 48-well plates
by use of Lipofectamine 2000 (Invitrogen). The AP-1 plasmid
(4AP-1 luciferase reporter plasmid [4AP-1-Luc]) was previously
described.42 In brief, the (AP-l)4-Luc contains four repeats (4) of
AP-1 binding sequences (TGAGTCA) under control of a luciferase
reporter.43 A total of 0.2 mg of plasmid DNA was applied. Addition-
ally, the base level of AP-1 was increased by phorbol myristate
acetate (PMA), a known activator of AP-1. Luciferase and b-galac-
tosidase activity was measured (Promega) after 24 hr of transfection.
An effective and signiﬁcant reduction of Luciferase activity was
reached with 10 mM of SR11302. Mesangial cells were co-treated
with 4ng/mL TGF-b and 10 mM of SR11302 before miR-21,
CTGF, and Col1a2 gene expression levels were determined by
qPCR.
Scratch Wound Healing Assay of Podocytes
WT5 podocyte cell line was cultured under non-permissive condi-
tions at 37C with RPMI (Life Technologies) supplemented with
10% FCS, 1% penicillin or streptomycin and without IFN-g. Tran-
sient liposomal transfection with pre-miR-21 or pre-neg was per-
formed as described above. The scratches in the cell monolayer
were generated with a 100 mL tip, and the cells were photographed
after 0 and 8 hr of migration with a Nikon Ti 90 microscope. Sub-
sequently, the cell-free area was calculated.
Annexin Apoptosis Assay
The detection of cells undergoing early apoptosis was performed by
Annexin V and 7-amino actinomycin D (7-AAD) staining using
the FlowCellectTM Annexin Red Kit (Millipore) according to
the manufacturer’s instructions. The analysis was performed by
ﬂuorescence-activated cell sorter analysis (FACS) on a Guava
easyCyteTM sorter (Millipore) using the Cytosoft software (Guava
Technologies).
Adenoviral Overexpression of Cdc25a and Cdk6 in Mesangial
Cells
Cdc25a and Cdk6 adenoviral gene expression vectors (pAV[Exp]-
CMV) were constructed by Vector Builder (Cyagen Biosciences).
Adenoviral MC transduction was performed in the presence of prot-
amine sulfate (4 ug/mL). The cells were infected with adenovirus vec-
tors at an MOI of 50. Eight hours after transduction, the medium was
changed to fresh medium. An adenovirus-expressing GFP (eGFP)
was used as control. Downstream analyses were performed 48 hr after
transduction.
Retroviral Overexpression of Pten in WT5 Podocytes
As previously described,44 helper-free recombinant retrovirus pro-
duced in supernatants of transfected amphotropic Phoenix packaging
cells was used to transduce WT5 podocytes.
Glycated Hemoglobin Count
Hemoglobin levels in blood samples taken at the study endpoint
(8 weeks of hyperglycemia) were assessed by use of a mouse he-
moglobin ELISA kit (Abcam). Glycated hemoglobin levels were
analyzed by mouse ELISA (CrystalChem). Glycated hemoglobin
levels are given as the percent of total hemoglobin count and in
mmol/mol.
Statistical Analysis
Average data are presented as mean and SEM unless otherwise stated.
All statistical analyses were performed with the SPSS package (SPSS,
Inc.) and GraphPad Prism software (GraphPad Prism Software).
Two-sided p values < 0.05 were considered statistically signiﬁcant
for all statistical procedures used. For the statistical comparison of
two groups, we used an unpaired two-tailed Student t test; for the
comparison of three or more groups, we used ANOVA followed by
Tukey post hoc tests. In the ﬁgures, p values are indicated: *p <
0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.
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